The role of α‐blockade in the treatment of hypertension can be reappraised in the light of a recently developed agent (indoramin) which overcomes the major drawbacks of earlier agents.
The medicinal chemistry involved in the discovery and synthesis of indoramin is summarized.
Highlights of the animal pharmacology of indoramin are outlined with reference to therapeutic utility as an antihypertensive agent.
The mode of action of indoramin can be described as competitive post‐synaptic α‐adrenoceptor antagonism combined with myocardial membrane stabilization.
Indoramin is an effective antihypertensive agent in man, without therapeutic problems associated with tachycardia, postural hypotension, tolerance, poor absorption, gastrointestinal disturbances, increased peripheral resistance or increased airways resistance. The pre‐clinical basis for these features has been reviewed.